Abstract: The compound 2-chloro benzaldehyde and 4-methoxy benzaldehyde when treated with potassium cyanid< and on further steam distillation 2-chloro-4,-methoxy benzoin was synthesized. On oxidation of 2-chloro-4" methoxy benzoin compound with concentrated nitric acid leads to the formation of 2-chloro-4"-methoxy benzil The yield of the title compound were good and their biological activity has been delineated. To obtain thi pharmacological data molecular docking studies were conducted. It also provides an evidence for the synthesizec compound antibacterial activity. The results showed that cell growth in vitro is significantly higher in gram positivi bacteria than in gram negative bacteria in different concentration dosages.
TECHNICAL FIELD OF INVENTION
The compound is characterized by IR, NMR AND TG DTA studies for determining the functional group presence of protons and thermal stability of the synthesized molecule. Biological assessment of designed ant synthetic molecule is done to assess the molecular docking efficacy and the anti bacterial activity for the compouru is carried out by disc diffusion method and. BACKGROUND AND PROBLEM WITH EXISTING ART
In our approach, we have selected benzil, a organic compound which is used in the treatment of cancer. Benzils an< its derivatives have attracted significant attention in the past decades. Benzil compounds having aromatic a diketone as a functional group are used as an antidepressant, astringent, anti-inflammatory, carminative, deodorant diuretic, expectorant, sedatives and antibacterial agents. Benzil derivatives exhibit radical scavenging, antibacteria and hypertensive (Mahabusarakam et al., 2004), antiprotozoal (Ganapaty et al., 2009), antiproliferative am antimitotic (Mousset et al., 2008) activities. The emergence and spread of antimicrobial resistance have become one of the most serious public health concern:
, .1 +.
across the world. The search for new antimicrobial compounds is a challenging task as bacteria are continuous!} developing resistance to antimicrobial compounds; however, infections due to such bacterial strains are infrequen although potentially fatal. Accordingly, the development of new antibacterial agents that could overcome thi resistance problem has become the subject of an ongoing research. The ever growing resistance to antibiotics lead; to continuous screening for new biologically effective compounds of either natural or synthetic origin. Molecular docking study is a well-established technique to determine the interaction of two molecules and find th< best orientation of ligand would form a complex with overall minimum energy. With this information we can fm< out new drugs and also make new synthetic compounds and lead molecules with different mechanism of action: and thereby different target organisms especially against drug resistant bacteria and emerging microbes.
SUMMARY OF THE INVENTION
The compound 2-ch!oro-4'-methoxy benzil is a more effective anti-bacterial agent. The anti bacterial activity for al the pathogens is also exhibited for the compound. The activity of the compounds were found to be dose dependen i.e., 100 ug/mL showed greater inhibition. A further study to obtain additional information relating t< pharmacological activity is in expansion. After studying the docking poses and binding modes of the docke< compounds, the necessity of hydrogen bond formation for enhancing the activity of this class of compounds can b< highly advocated. LIST OF PREFERRED AND OPTIONAL FEATURES
1. Synthesis of the compound 2-chloro-4'-methoxy benzil has anti bacterial activity.
2. Characterisation of the synthesised compound by IR, NMR and UV analysis.
3. Biological activity and docking study is carried out for the compound 2-chloro-4'-methoxy benzil.
BRIEF DESCRIPTION OF THE DRAWING
Figure 1: Development of the compound 2-chloro-4'-methoxy benzil.
Figure 2(a): IR analysis
Figure 2(b): NMR analysis
Figure 2(c): UV analysis
Figure 3: Docking activity of 2-chloro-4'-methoxy benzyl
Table 1: Antibacterial assay of 2-chloro-4'-dimethoxy benzil by disc diffusion method
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
The title compound was synthesized by benzoin condensation using 4 g of K.CN dissolved in 75cc of water in a om litre flask. To this was added 0.005 mole% of 4-methoxy benzaldeyde and 2-chloro benzaldeyde. It is then mixe<
with 75cc of ,95% ethanol. The mixture formed a solution at the boiling temperature and was refluxed for tw< hours. Steam was then passed through the solution until all the alcohol and nearly all the unchanged aldehyde wen removed. The condensed water was decanted from the product and then the crude 2-chloro-4'-methoxy benzoii obtained is treated with 10 ml concentrated nitric acid. It is then heated over in a water bath for one hour and latte. set aside for crystallization. The product was then pressed as free as possible from oily material on a suction funne and washed with cold alcohol. In this way about 75% of crude product was obtained. The yield of pure 2-chloro-4' methoxy benzil amounted to 60% of the expected product.
| Section | Controller | Decision Date |
|---|---|---|
| # | Name | Date |
|---|---|---|
| 1 | 202141001362-Form9_Early Publication_12-01-2021.pdf | 2021-01-12 |
| 1 | 202141001362-US(14)-HearingNotice-(HearingDate-28-02-2022).pdf | 2022-02-02 |
| 2 | 202141001362-Form18_Examination Request_12-01-2021.pdf | 2021-01-12 |
| 2 | 202141001362-FER.pdf | 2021-10-18 |
| 3 | 202141001362-Form-5_As Filed_12-01-2021.pdf | 2021-01-12 |
| 3 | 202141001362-Claims_FER Reply_14-09-2021.pdf | 2021-09-14 |
| 4 | 202141001362-Form-3_As Filed_12-01-2021.pdf | 2021-01-12 |
| 4 | 202141001362-Correspondence_FER Reply_14-09-2021.pdf | 2021-09-14 |
| 5 | 202141001362-Form-1_As Filed_12-01-2021.pdf | 2021-01-12 |
| 5 | 202141001362-Abstract_As Filed_12-01-2021.pdf | 2021-01-12 |
| 6 | 202141001362-Form 2(Title Page)Complete_12-01-2021.pdf | 2021-01-12 |
| 6 | 202141001362-Claims_As Filed_12-01-2021.pdf | 2021-01-12 |
| 7 | 202141001362-Drawing_As Filed_12-01-2021.pdf | 2021-01-12 |
| 7 | 202141001362-Correspondence_As Filed_12-01-20210001.pdf | 2021-01-12 |
| 8 | 202141001362-Description Complete_As Filed_12-01-2021.pdf | 2021-01-12 |
| 9 | 202141001362-Drawing_As Filed_12-01-2021.pdf | 2021-01-12 |
| 9 | 202141001362-Correspondence_As Filed_12-01-20210001.pdf | 2021-01-12 |
| 10 | 202141001362-Claims_As Filed_12-01-2021.pdf | 2021-01-12 |
| 10 | 202141001362-Form 2(Title Page)Complete_12-01-2021.pdf | 2021-01-12 |
| 11 | 202141001362-Form-1_As Filed_12-01-2021.pdf | 2021-01-12 |
| 11 | 202141001362-Abstract_As Filed_12-01-2021.pdf | 2021-01-12 |
| 12 | 202141001362-Form-3_As Filed_12-01-2021.pdf | 2021-01-12 |
| 12 | 202141001362-Correspondence_FER Reply_14-09-2021.pdf | 2021-09-14 |
| 13 | 202141001362-Form-5_As Filed_12-01-2021.pdf | 2021-01-12 |
| 13 | 202141001362-Claims_FER Reply_14-09-2021.pdf | 2021-09-14 |
| 14 | 202141001362-Form18_Examination Request_12-01-2021.pdf | 2021-01-12 |
| 14 | 202141001362-FER.pdf | 2021-10-18 |
| 15 | 202141001362-US(14)-HearingNotice-(HearingDate-28-02-2022).pdf | 2022-02-02 |
| 15 | 202141001362-Form9_Early Publication_12-01-2021.pdf | 2021-01-12 |
| 1 | IntellectualPropertyIndiaE_25-03-2021.pdf |